Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
复制标题
Syndecan-4 作为生物标志物来预测 WT1 肽疫苗治疗的多形性胶质母细胞瘤的临床结果。
DOI：
10.4155/fsoa-2015-0008
复制
发表时间：
2016-12
影响因子：
2.5
通讯作者：
Sugiyama H
中科院分区：
文献类型：
--
作者：
Takashima S;Oka Y;Fujiki F;Morimoto S;Nakajima H;Nakae Y;Nakata J;Nishida S;Hosen N;Tatsumi N;Mizuguchi K;Hashimoto N;Oji Y;Tsuboi A;Kumanogoh A;Sugiyama H
在癌症免疫治疗中，生物标志物对于识别有反应的患者很重要。本研究旨在寻找预测WT 1肽疫苗接种临床结果的生物标志物。通过外周血单核细胞的cDNA微阵列分析鉴定在长期和短期存活者之间差异表达的候选基因，所述外周血单核细胞在疫苗接种之前从30名胶质母细胞瘤患者（发现集）中提取，并使用发现集和不同的23名患者（验证集）通过定量RT-PCR进行验证。 SDC-4 mRNA表达水平在长期和短期生存者之间存在差异：SDC 4低和高患者的1年生存率分别为64.0%和18.5%。 SDC-4是一种新的预测WT 1肽疫苗效力的生物标志物。最近，癌症免疫疗法正在成为标准的治疗选择。为了提高其疗效，生物标志物的鉴定对于选择响应患者是重要的。在这项研究中，我们确定了SDC-4作为生物标志物，以预测临床结果，使用外周血单核细胞从恶性脑肿瘤胶质母细胞瘤患者，谁与WT 1肽疫苗治疗。用30份免疫前外周血单个核细胞样本，通过基因芯片筛选出32个候选基因，最后用另外23份样本进行RT-PCR验证，只筛选出SDC-4基因。因此，SDC 4低和高患者的1年生存率分别为64.0%和18.5%。
In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination. Candidate genes that were expressed differentially between long- and short-term survivors were identified by cDNA microarray analysis of peripheral blood mononuclear cells that were extracted from 30 glioblastoma patients (discovery set) prior to vaccination and validated by quantitative RT-PCR using discovery set and different 23 patients (validation set). SDC-4 mRNA expression levels distinguished between the long- and short-term survivors: 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively. SDC-4 is a novel predictive biomarker for the efficacy of WT1 peptide vaccine. Recently, cancer immunotherapies are becoming a standard therapeutic option. To improve their efficacy, identification of biomarkers is important to select responsive patients. In this study, we identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine. With 30 samples of peripheral blood mononuclear cells prior to vaccination, 32 candidate genes were filtrated by microarray, and finally only SDC-4 was validated by RT-PCR using another 23 samples. Accordingly, 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively.